A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
AGIOS PHARMACEUTICALS, INC. operates in the Pharmaceutical Preparations industry, Healthcare sector. Full business description from SEC filing not yet available.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 0 |
| Net Income | -413M | -413M | 674M | -352M | -232M | 1.6B |
| EPS | $-7.12 | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 |
| Free Cash Flow | -377M | -377M | 388M | -297M | -314M | -413M |
| ROIC | -32.6% | -30.2% | 43.7% | -36.8% | -19.4% | 189.7% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.03 | 0.03 | 0.04 | 0.16 | 0.00 | 0.00 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -472M | -472M | -426M | -391M | -389M | -378M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | -34.6% | -30.2% | 43.7% | -36.8% | -19.4% | 189.7% |
| Shares Outstanding | 58M | 58M | 58M | 56M | 55M | 60M |
AGIOS PHARMACEUTICALS, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average ROIC is 29.4%. At current prices, the estimated annualized return to fair value is +3.8%.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a 5-year average return on invested capital (ROIC) of 29.4%. This indicates strong capital allocation and a potential competitive advantage.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a market capitalization of $1.9B. It is classified as a small-cap stock.
AGIOS PHARMACEUTICALS, INC. (AGIO) does not currently pay a regular dividend.
AGIOS PHARMACEUTICALS, INC. (AGIO) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
AGIOS PHARMACEUTICALS, INC. (AGIO) generated $-377 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a debt-to-equity ratio of 0.03. This indicates a conservatively financed balance sheet.
AGIOS PHARMACEUTICALS, INC. (AGIO) reported earnings per share (EPS) of $-7.12 in its most recent fiscal year.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a return on equity (ROE) of -30.2%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 15 years of financial data for AGIOS PHARMACEUTICALS, INC. (AGIO), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
AGIOS PHARMACEUTICALS, INC. (AGIO) has a book value per share of $20.58, based on its most recent annual SEC filing.